

C2 Sub 23

24. (amended) The immune adjuvant composition as claimed in claim 19, wherein the immunostimulatory oligonucleotide comprises more than one unmethylated CpG dinucleotide.

C3 Sub 25

27. (amended) The immune adjuvant composition as claimed in claim 19, wherein the immunostimulatory oligonucleotide comprises a CpG motif having the formula 5'X<sub>1</sub>CGX<sub>2</sub>3', wherein X<sub>1</sub> is adenine, guanine, or thymine, and X<sub>2</sub> is cytosine, thymine, or adenine.

28. (amended) The immune adjuvant composition as claimed in claim 27, wherein the CpG motif comprises TCTCCCAGCGTGCGCCAT.

C4

32. (amended) The immune adjuvant composition as claimed in claim 19, further comprising an antigen selected from the group consisting of a protein, a peptide, a polysaccharide, a lipid, a glycolipid, a phospholipid, and a nucleic acid encoding the protein or peptide.

C5 Sub 26

54 (amended) The method as claimed in claim 49, wherein the immunostimulatory oligonucleotide comprises more than one unmethylated CpG dinucleotide.

C6

57 (amended) The method as claimed in claim 49, wherein the immunostimulatory oligonucleotide comprises a CpG motif having the formula 5'X<sub>1</sub>CGX<sub>2</sub>3', wherein X<sub>1</sub> is adenine, guanine, or thymine, and X<sub>2</sub> is cytosine, thymine, or adenine.

Sub 26

58. (amended) The method as claimed in claim 57, wherein the CpG motif comprises TCTCCCAGCGTGCGCCAT.

Please add the following new claims as follows:

Sub D1  
C7

63. (new) An immune adjuvant composition comprising  
(a) a saponin adjuvant; and  
(b) an immunostimulatory oligonucleotide comprising at least one unmethylated CpG motif,

wherein the saponin/adjuvant comprises substantially pure QS-7, QS-17 or QS-18.

64. (new) A method for increasing the immune response to an antigen in an individual or a test system to which the antigen is administered comprising administering an effective amount of an immune adjuvant composition as claimed in claim 63.

65. (new) An immune adjuvant comprising  
(a) a saponin adjuvant; and  
(b) an immunostimulatory oligonucleotide comprising at least one unmethylated CpG motif,  
wherein the immunostimulatory oligonucleotide is modified.

66. (new) The immune adjuvant composition as claimed in claim 65, wherein the immunostimulatory oligonucleotide is modified with at least one phosphorothioate-modified nucleotide.

67. (new) A method for increasing the immune response to an antigen in an individual or a test system to which the antigen is administered comprising administering an effective amount of an immune adjuvant composition as claimed in claim 65.

68. (new) A method for increasing the immune response to an antigen in an individual or a test system to which the antigen is administered comprising administering an effective amount of an immune adjuvant composition as claimed in claim 66.

69. (new) An immune adjuvant comprising  
(a) a saponin adjuvant; and  
(b) an immunostimulatory oligonucleotide comprising at least one unmethylated CpG motif,

wherein the immunostimulatory oligonucleotide comprises TCTCCCAGCGTGCGCCAT.

Sub E3 70. (new) A method for increasing the immune response to an antigen in an individual or a test system to which the antigen is administered comprising administering an effective amount of an immune adjuvant composition as claimed in claim 69.

C Sub D10  
CONT. 71. (new) An immune adjuvant compositing comprising  
(a) a saponin adjuvant; and  
(b) an immunostimulatory oligonucleotide comprising at least one unmethylated CpG motif,

wherein the immunostimulatory oligonucleotide comprises  
TCCATGACGTTCTGACGTT.

Sub E4 72. (new) A method for increasing the immune response to an antigen in an individual or a test system to which the antigen is administered comprising administering an effective amount of an immune adjuvant composition as claimed in claim 71.

Sub D11 73. (new) An immune adjuvant compositing comprising  
(a) a saponin adjuvant; and  
(b) an immunostimulatory oligonucleotide comprising at least one unmethylated CpG motif,

wherein the immunostimulatory oligonucleotide is from 5-40 base pairs in length.

Sub E5 74. (new) A method for increasing the immune response to an antigen in an individual or a test system to which the antigen is administered comprising administering an effective amount of an immune adjuvant composition as claimed in claim 73.

Sub D12 75. (new) An immune adjuvant compositing comprising